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Abstract
Background: The global mortality caused by cardiovascular disease increases with weight. The Framingham study
showed that obesity is a cardiovascular risk factor independent of other risks such as type 2 diabetes mellitus,
dyslipidemia and smoking. Moreover, the main problem in the management of weight-loss is its maintenance, if it
is achieved. We have designed a study to determine whether a group motivational intervention, together with
current clinical practice, is more efficient than the latter alone in the treatment of overweight and obesity, for initial
weight loss and essentially to achieve maintenance of the weight achieved; and, secondly, to know if this
intervention is more effective for reducing cardiovascular risk factors associated with overweight and obesity.
Methods: This 26-month follow up multi-centre trial, will include 1200 overweight/obese patients. Random
assignment of the intervention by Basic Health Areas (BHA): two geographically separate groups have been
created, one of which receives group motivational intervention (group intervention), delivered by a nurse trained
by an expert phsychologist, in 32 group sessions, 1 to 12 fortnightly, and 13 to 32, monthly, on top of their
standard program of diet, exercise, and the other (control group), receiving the usual follow up, with regular visits
every 3 months.
Discussion: By addressing currently unanswered questions regarding the maintenance in weight loss in obesity/
overweight, upon the expected completion of participant follow-up in 2012, the IMOAP trial should document, for
the first time, the benefits of a motivational intervention as a treatment tool of weight loss in a primary care
setting.
Trial Registration: ClinicalTrials.gov Identifier: NCT01006213
Background
Introduction
Overweight and obesity are growing health problems
throughout the industrialised world. If not controlled, it
then will continue to contribute to the burden of non-
transmitable diseases, which is increasing constantly.
There is currently clear scientific evidence of the
association of obesity and a large number of diseases
and their manifestations, including: diabetes, hyperten-
sion, dyslipidemia, cardiovascular events and inflamma-
tory markers such as plasma fibrinogen levels and C-
reactive protein [1,2].
Overall mortality for cardiovascular causes increases
with weight [3,4] and, in the Framingham study, obesity
was seen to be an independent risk factor for CVR
regardless of other risk factors such as type 2 diabetes
mellitus, dyslipidemia and smoking [5,6]; at the same
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reduces life expectancy, in both women and men and
smokers and non-smokers [7].
The prevalence of obesity is increasing continuously in
developed countries, causing a serious public health pro-
blem. According to the SEEDO’2000 study, the figures
for the prevalence of obesity in Spain (BMI>30) are
14.5% (13.3% men and 15.7% women) while the overall
overweight and obesity figure (BMI>25) is 53.5% [8,9].
When treating overweight and obesity, it is considered
essential that diet should be included in a general pro-
gramme, together with physical exercise, lifestyle
changes and psychological support. However, although
significant weight loss can be relatively easily achieved
in the short term, its maintenance is very difficult to
get, is for this that the research that could help these
patients is so important. Drug treatment of obesity
should not be used as an isolated therapy, but together
with other basic therapies, such as diet, physical activity
and psychological support. It should be prescribed to
patients with BMI>30 or >27 if associated with co-mor-
bidities, such as diabetes mellitus, arterial hypertension,
dyslipidemia, sleep apnoea syndrome [10-13].
Weight loss is a healthcare need that leads to significant
savings in the estimated cost of obesity and the diseases
associated to it, both directly and indirectly, which amount
to more than 2,500 million euros per annum, a figure that
accounts for almost 7% of total healthcare costs [14,15].
A variety of individual and group psychological thera-
pies have been used in weight loss. In a study conducted
in 20 primary healthcare centres in Great Britain,
researchers evaluated the efficacy of a motivational inter-
view to modify fat intake, physical activity and smoking
in 883 patients at high risk of cardiovascular disease,
obtaining a benefit in the intervention group [16].
Motivational intervention alone, in obese patients, has
been shown to be effective, even in patients who only
took a drug (sibutramine) for weight reduction [17]. But
psychological interventions are particularly useful when
combined with dietary and exercise strategies. In this
review of 36 clinical studies, 26 were conducted in the
United States, and only one in Spain, in diabetic obese
patients [18,19].
Other studies using motivational interviews have been
shown to be effective for giving up smoking [14,17], redu-
cing alcohol intake [20,21] and improved adherence to
treatment strategies in diseases as common as arterial
hypertension, diabetes mellitus and bronchial asthma [22].
When making lifestyle changes in the adult popula-
tion, the interventional methods are complex, because
individuals tend to cling to what is familiar, even though
this may be putting their health at risk [23].
All changes involve some elements that evolve and
others that remain stable. The aim is to help patients
make them part of their lives without affecting what
they feel is essential. However, it is important to help
them perceive these as necessary and beneficial so that a
series of changes they make will give them an awareness
that their health depends on the type of habits they
change, and that these can be taken as an exercise that
will improve their health and well-being[21].
However, there are no studies in our primary care
environment, in cardiovascular disease, that assess the
efficacy of an intervention based on a group motivation
interview about weight reduction in overweight and
obese patients, and the maintenance of the weight
achieved over time.
Studies are required among our patients to confirm
the efficacy observed in other populations and the feasi-
bility of the group motivation intervention in overweight
and obese patients, with a view to suggesting its applica-
tion in the primary care setting as a tool for dealing
with this health problem.
For these reasons, a study has been proposed, to com-
pare the efficacy of the healthcare professionals’ usual
practices, together with a motivational group interven-
tion vs an isolated traditional intervention on weight
loss and its maintenance in overweight and obese
patients (IMOAP). The purpose of this report is to pre-
sent the design of IMOAP trial.
Methods
Study overview
This study will be randomised, multi-centre interven-
tional, in overweight and obese patients, with a follow-
up of 26 months.
The overall goal of IMOAP study is to assess whether
the efficacy of the healthcare professionals’ usual prac-
tices, together with a motivational group intervention
(delivered by a nurse trained by an expert psychologist),
is more effective than an isolated traditional intervention
on weight loss and its maintenance in overweight and
obese patients. Furthermore, the study will evaluate
whether this result has a positive impact on quality of
life, changes in eating habits, and a reduction in the
associated cardiovascular risk factors and overall cardio-
vascular risk.
T a b l e1p r e s e n t st h et i m e l i n eo ft h es t u d y .P r o t o c o l
development, external review occurred over an initial
4-month period beginning in 2007.
A second phase had the purpose of the acceptance to
participate of Basic Health Areas.
For this, the coordinators have contacted the Basic
Health Areas, to explain the protocol and confirm their
participation. After this period, it has been the distribu-
tion and randomisation into the study groups: Interven-
tion/controls. For those BHA that will visit the
intervention groups, it has been done the training of
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plates and study protocols.
The training of the nursing staff has consisted in a
basic training strategy, initially aimed at nurses and
focusing on group motivation for life-style changes in
overweight and obese patients, because lack of motiva-
tion is a common cause of therapeutic failure. The
training has consisted of a number of workshops where
role play techniques have taken place to help assimilate
the concepts taught. This workshop has been delivered
at the BHA of the intervention group and written mate-
rial delivered regarding the content. Secondly, a written
guide has been created to standardise the information
the nurses provide during the overweight and obesity
check-up visits. The guide includes information about
the disease, healthy habits and diet.
Randomization into the study began in first trimester
2008, with a recruitment goal of 1,200 participants. The
intervention and main trial recruitment will take place
over 30 months with the patients in the intervention
and control groups.
Finally, four months before the end of the project the
final laboratory tests will be performed and the data col-
lected for statistical analysis and reporting.
The first patient was entered on September 2008. The
final visit for the last randomized participant is planned
for the last trimester 2010, with final study reports
expected in the first trimester of 2013.
Selection of the study subjects
The IMOPAP inclusion and exclusion criteria are pre-
sented in Table 2. These criteria have been established
to identify a trial population with overweight and obe-
sity, and with sufficient statistical power with the pro-
posed sample size. They will be included sequentially,
from the beginning of the study. To avoid possible bias
in the selection of patients, and not overburden the nur-
sing staff, patient recruitment and follow up will be
rolled out in stages during the first six months of the
study to the first two patients who meet the study inclu-
sion requirements and who present none of the exclu-
sion criteria. This will carry out superior quality control,
using smaller sample size than would be possible if we
randomised the patients. The institutional review Ethics
Committee of Jordi Gol i Gurina Foundation in Barce-
lona approved the conduct of the study. In addition, the
study has been done in compliance with the Helsinki
Declaration. Each IMOAP participant has provided writ-
ten informed consent using procedures reviewed and
approved by the EECC review board.
Measurements
A wide range of interview, physical examination, and
laboratory data are being collected (Table 3), with the
frequency of measurement varying by group assignment,
but at least at baseline, at one year and at the end of the
trial. The weight measurement will be done always in
Table 1 Timetable of the IMOAP trial
Phase No. of Months Calendar Dates Trial Activities
1 4 01/07-04/07 Protocol development.
2 8 05/07-12/07 Acceptance to participate of Basic Health Areas.
3 2 01/08-02/08 Distribution and randomisation of the Basic Health Areas into both groups: Intervention/controls.
For those BHA that will visit the intervention groups, training of nursing staff and coordinating
the teams, creating templates and study protocols.
4 30 03/08-09/10 Main trial recruitment and follow-up
5 26 10/10-12-12 Follow-up only
6 4 12/12-04/13 Analysis and reporting
Table 2 Inclusion and exclusion criteria
Inclusion criteria
1. Overweight (BMI>25) and obese (BMI>30) patients of both genders, registered in the medical history (MH) or recently diagnosed.
2. Aged between 30 and 70 years
3. Agreement to participate in the study
Exclusion criteria
1. Patients with severe clinical pathology (bedridden, dementia, advanced neoplasia, etc.)
2. Patients with secondary obesity (hypothyroidism, Cushing’s disease, etc)
3. Patients with severe sensorial disorders capable of interfering with the motivational intervention (severe, uncorrected deafness, severe visual
deficit, etc).
4. Patients with serious psychiatric disorders
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only, barefoot, and at the same time of day). Body Mass
Index (BMI) will be calculated as: Weight in kilos
divided by height in square metres W (kg)/H (m2).
Waist measurement will be defined as the midline
between the edge of the lowest rib and the iliac crest
alongside the anterosuperior iliac spine, in cm. The car-
diovascular risk factors will also be assessed: Hyperten-
sion will be defined as either blood pressure readings of
above 140/90 on three occasions, (in diabetics, above
130/80); or patients receiving treatment for hypertension
or with a clinical diagnosis of hypertension; Diabetes
Mellitus: By case history or two prandial glycaemia read-
ings > 126 mg/dl; -Smoking: packets year.
Quality of life and food assessment through SF ques-
tionnaire 36 validated in Spain by Alonso [24], and diet-
ary survey, 3 day record, (quantitative and qualitative) at
the beginning and end of the study [25].
A questionnaire, drafted specifically for this study, and
administered by the participating nurse, gathers the vari-
ables mentioned.
Outcomes
The primary endpoint for the IMOAP is to assess
whether the efficacy of the healthcare professionals’
usual practices, together with a motivational group
intervention (delivered by a nurse trained by an expert
psychologist), is more effective than an isolated tradi-
tional intervention on weight loss and its maintenance
in overweight and obese patients.
This will be calculated as the percentage of patients
reducing their weight by 5% and maintenance over time.
The strategies for facing change and working in the
groups [26-28] consist in providing information and
practical advice on modifying eating habits, starting or
increasing regular physical activity, lifestyle changes,
functioning of the metabolism, management of the obe-
sity and its complications, smoking as a cardiovascular
risk factor, food diary, shopping methods and, finally,
the number of calories to ingest.
Formation of the patient groups
Groups will be made up according to the following cri-
teria: mixed, women and men, aged between 30 and 70
years, and a maximum 15 and minimum 7 members per
group. Each nurse could manage 3 different groups
(1 per month). The random assignment of the interven-
tion will be done at the primary care Basic Health Areas
(BHA), in L’Hospitalet de Llobregat, neighbouring areas
and Barcelona city. Two groups will be formed in sepa-
rate centres, one of which will receive the motivational
group intervention (intervention group) and the other
the standard treatment (control group). To prevent possi-
ble bias, the BHA located in the same building will be
assigned to the same group (control or intervention). The
participating healthcare professional (nurse) will select
the first two patients with visits during the pre-estab-
lished recruitment period, who met the study criteria.
Intervention control group
Participants will follow the usual intervention, according
to the protocols in each centre, as it is described else-
where [8]. The visits will be done every 3 months,
including advice on life-style changes, physical exercise,
hypo caloric diet, containing 1,200-1,500 kcal and
anthrometric measurements (weight, height and waist
perimeter). Follow up of blood tests by a healthcare pro-
fessional will be done at the beginning, at one year and
at the end of the study. In additional file 1 it is
described the content of their visits.
Motivational intervention in the intervention group
Participants will follow the usual intervention, the same
as in the control group, plus a group motivational inter-
vention every 15 days, at the initial weeks 1 and 12 of
the intervention, following the LEARN (Lifestyle,
Table 3 Measures
1. Questionnaires
a. Sociodemographics: age, ethnicity, sex.
b. Detailed initial medical history; abbreviated interval history focused on eligibility criteria, CVD, smoking status and diabetes mellitus. Inter-
current processes: diseases, level of care they have received, start and end of the process.
c. Concomitant medications:
d. Quality of life and food assessment through SF questionnaire 36 validated in Spain by Alonso [24]
e. Dietary survey, 3 day record, (quantitative and qualitative) at the beginning and end of the study [25].
f. Questionnaire drafted specifically for this study, described in table 4.
2. Physical examination measures
a. Anthropometric measurements: standing height in centimetres (cm), weight in kg, waist circumference
b. BP and pulse
3. Laboratory measures
a. Fasting serum glucose
b. Fasting lipid panel (Total Cholesterol, HDL-Cholesterol, LDL- Cholesterol)
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gramme [12] and then monthly at weeks 13 and 32, fol-
lowing the instructions of the Weight Maintenance
Survival Guide programme [13]. Each session would last
for one hour, for a 26 month follow up period, with a
total of 32 interventions, as described in Table 4.
R e q u e s tf o rb l o o dt e s ta tt h es t a r t ,a to n ey e a ra n da t
the end (3-year study duration). In additional file 2 it is
described contents of the visit.
Objectives of the psychological support
Table 5 describes the main objectives proposed for the
interventional group, aimed to facilitate the awareness
and compliance with a series of requirements for
Table 4 32 group sessions of the intervention
In sessions 1 to 4 (fortnightly) we should raise awareness among the patients of the benefits of changing their habits, which will allow us to move
from the “pre-contemplation” to the “contemplation” stage.
To do this we must provide them with ample information about the benefits of change, the recommended diets which will be dealt with
individually with the nurse or doctor, physical exercise, etc.
This will be reinforced with the instructions given to individuals.
1. We will explore their fears, earlier failures, worries and difficulties that prevent them from taking the decision.
2. We will help sort out their doubts about unhealthy behaviour or habits to encourage life style changes towards a healthier life.
3. We will give them the tools they need to face situations where their usual strategies have failed.
4. We will encourage the patient to move towards the desire to change, attempting to help them recognise and take care of their present and
future problems and strengthening their perception of the effects.
5. We will work on the patients’ resistance.
In sessions 5 to 12 (fortnightly) we will have dispelled the patients’ doubts and they will feel motivated to make a change to healthy habits and be
committed to continuing with the programme.
We will then move into the “determination” stage
1. Reinforce the patient’s self-motivational affirmations.
2. Point out the positive and negative aspects of the behaviour to suppress, the old and the new to be acquired.
3. Elaborate on these by asking for examples, clarifying the how, when, why...
4. Use extremes and image the best and worst results of the changes as well as their possible consequences.
5. Look backwards and/or forwards. Visualise with the patient what it was like before and how he/she thinks, he/she is going to feel once he/
she has given up this unhealthy habit.
6. Explore the feelings associated with the change (fear, anxiety, etc)
7. Explore if he has help and support from a partner/family.
8. Strengthen the active role the patient has in the change.
9. Understand the resistance to change.
10. Help develop strategies.
11. Develop a joint action plan
12. Combat feelings of loss caused by the change.
In sessions 13 to 32 (monthly) work with “changes” and “maintenance”.
1. Bolster the capacity to change
2. Encourage the patients to give their own reasons.
3. Increase the consciousness towards change.
4. Understand the stress these changes in habits cause in the patients
5. Reinforce the benefits of change.
6. Bolster self-efficacy.
7. Support the changes.
8. Boost each member’s capacity to make a change.
9. Understand the patients’ emotions and thoughts.
10. Give empathetic responses.
11. Assist with the expression of feelings and emotions.
12. Prevent relapses through exploration
13. Identify risky situations and find strategies for dealing with them.
14. Support the work and efforts made and the benefits of change and maintenance of their decision.
From 1 to 12, fortnightly sessions, from 13 to 32, monthly sessions.
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up by creating intervention groups with psychological
support to be conducted by nursing staff (previously
trained by expert psychologists), [26,27]:
The Stages through which the patient passes before
taking the decision to change his or her habits, following
the Prochaska model [29], are described in Table 6.
Sample size calculation
The number of subjects necessary to divide into two
independent groups has been calculated. With the stan-
dard intervention, a weight r e d u c t i o no f5 %o fw e i g h ti s
expected (P1) [30,31]. It was predicted that the experi-
mental intervention would lead to 75% of the patients
reducing their weight by 5%. It will be assumed an
a l p h ar i s ko f0 . 0 5( b i l a t e r a l hypothesis) and a beta risk
of 0.20 (a potential 80%). If the interventions will be
assigned individually, in other words, per patient, the
number of patients in each group would be 328 (756 in
total). If we assume a percentage loss of 20% and apply
a correction according to the formula Na = N [1/1-R)]
where N is the theoretical number of subjects, Na is the
corrected number of subjects and R is the expected pro-
portion of loss, a total of 946 patients would be neces-
sary. Given that the assignment of the interventions will
be done by BHA, we had to increase the sample size
because of the design effect [28]; if 24 BHA (clusters)
were to participate, 12 per type of information, it would
be K = [m(1-CCI)]/[Z-(CCI × m)] where K = number of
subjects per cluster, m = 473 patients per intervention,
Z = number of clusters per type of intervention = 12 and
ICC = intra-class correlation coefficient. We assumed that
the basic ICC for the percentage of obese patients who
would reduce their weight by 5% was 0.005. The number
of patients in each BHA (Cluster) would be 50. 50 subjects
× 12 BHA = 600 patients per arm or type of intervention.
600 subjects × 2 interventions = a total of 1,200 patients.
Statistical analysis
A descriptive statistical analysis will be made according
to the variables. For the quantitative variables, using the
mean and standard deviation, for the qualitative ones,
proportions will be used. The data analysis will include
an evaluation of the initial comparability of the patients
in the two types of intervention using bivariate techni-
ques: The Chi-Square for the proportions and, in the
case of the mean, the Student’s t-distribution or its non-
parametric equivalent when necessary, by point estima-
tion with a confidence interval of 95%.
The hypothesis to compare will be the null hypothesis,
defined as equal efficacy of the usual and experimental
interventions (both interventions achieved a weight loss
of 5% in the same proportion of patients). The possible
difference in efficacy between the interventions will be
carried out through an analysis based on the individual
values of the patients using multilevel statistical techni-
ques [32].
Discussion
Overweight and obesity, serious and growing health pro-
blems, are not receiving the attention they deserve from
primary care practitioners. An additional problem
related to weight loss, if achieved, is its maintenance.
The study IMOAP analyses the management of over-
weight and obesity, in a group motivational intervention,
managed by a nurse trained by an expert psychologist,
in addition to usual practice, to see if this intervention
is more efficient than the latter alone in the treatment
of overweight and obesity in relation to percentage
weight loss and maintenance. Also, if so, if it would it
be possible to reduce the prevalence of classic and
emerging cardiovascular risk factors that are related to
Table 5 Objectives of the physcological support
￿Give patients the opportunity to explain their difficulties, to achieve the
required objectives.
￿Share their experiences and feelings with one another from their
group team.
￿Enable the appearance and elaboration on the anxiety that arises with
lifestyle changes.
￿Reinforce the changes made.
￿Explain the benefits of these new attitudes.
￿Clear up any doubts.
￿Induce shared positive reinforcement.
Table 6 Stages in the intervention group
A) Pre-
contemplation
1. Give the patient plenty of advice 2. Guide the patient in relation to the programme 3. Get commitment through the
motivational interview. 4. Evaluate the willingness and motivation to make changes.
B) Contemplation 1. Evaluate willingness and motivation to make the changes 2. Get a realistic commitment through the motivational interview
3. Reach an agreed decision to change behaviour and habits.
C) Preparation for
action
1. Create an action plan within the group, adapting this to individual possibilities 2. Invite the family to collaborate.
D) Action 1. Introduce initiation of prevention of relapses during the group sessions. 2. Introduce advice, educational activities about
healthy eating habits and smoking. 3. Include reinforcement for achievements.
E) Maintenance 1. Introduce maintenance of prevention of relapses during the group sessions 2. Maintain the reinforcement for the
achievements made, highlighting the health benefits.
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cular conditions.
The results of IMOAP trial should provide substantial
direction regarding weight loss management at a pri-
mary care, and it could be introduced as a basic treat-
ment tool for overweight and obese patients.
Additional file 1: Control definite
Additional file 2: Intervention
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